Fmoc-2,4-Dimethyl-L-phenylalanine: Properties & SPPS Use

Fmoc-2,4-Dimethyl-L-phenylalanine is a sterically defined, Fmoc-protected non-canonical amino acid building block designed for incorporation into peptides via standard solid-phase peptide synthesis (SPPS) protocols, enabling researchers to introduce defined steric and electronic modifications at the phenylalanine side chain.

Full Chemical Name

Fmoc-2,4-Dimethyl-L-phenylalanine

SKU

F700506

Amino Acid Class

Non-canonical / unnatural Fmoc-protected amino acid

Stereochemistry

L-configuration (S)

Protection Strategy

Fmoc on α-amine; free carboxylic acid for resin coupling

Primary Application

Fmoc solid-phase peptide synthesis (SPPS)

Side-Chain Modification

Methyl groups at ortho (2) and para (4) positions of phenyl ring

Chemical Identity and Structure

Fmoc-2,4-Dimethyl-L-phenylalanine is a synthetic, non-canonical amino acid in which the phenyl ring of L-phenylalanine bears methyl substituents at the 2- (ortho) and 4- (para) positions. The α-amine is protected by the base-labile 9-fluorenylmethoxycarbonyl (Fmoc) group, the standard protecting group for Fmoc SPPS workflows. The free carboxylic acid terminus is available for direct coupling to resin-bound amines or to the N-terminus of a growing peptide chain using standard activators such as HATU, HBTU, or DIC/Oxyma.

The introduction of two methyl groups on the aromatic ring increases the steric bulk of the side chain relative to native phenylalanine and alters the electron density of the ring, which can influence π-stacking interactions, hydrophobic packing within peptide helices, and receptor-binding geometry. The L-configuration ensures compatibility with ribosome-independent, chemically synthesized peptide libraries as well as structure–activity relationship (SAR) studies where stereochemical control is paramount.

Role in Fmoc Solid-Phase Peptide Synthesis

Fmoc SPPS is the dominant method for the synthesis of research-grade peptides, proceeding through iterative cycles of Fmoc deprotection with piperidine (typically 20% in DMF) followed by amino acid coupling. Fmoc-2,4-Dimethyl-L-phenylalanine slots directly into this workflow as a standard Fmoc building block without requiring modified deprotection conditions.

Because the 2-methyl (ortho) substituent introduces steric congestion adjacent to the reactive carbonyl, coupling efficiency may be reduced compared to unhindered residues. Researchers are advised to consider double-coupling protocols or the use of more reactive activating agents (e.g., HATU with a hindered base such as 2,6-lutidine or collidine) when incorporating this building block, particularly when it is flanked by other bulky residues. Monitoring coupling completeness with a ninhydrin (Kaiser) test or chloranil test is recommended.

Synthesis scale, resin choice (e.g., Wang resin for C-terminal acids, Rink amide resin for C-terminal amides), and cleavage/deprotection conditions (standard TFA cocktails) are generally compatible with this building block, as it bears no additional side-chain protecting groups beyond the Fmoc on the amine.

Applications in Peptide Research and Drug Discovery

Non-canonical amino acids such as Fmoc-2,4-Dimethyl-L-phenylalanine are widely used in medicinal chemistry and chemical biology to improve the properties of lead peptides. Key application areas include:

• Metabolic stability: Alkyl substitution on the aromatic ring can reduce susceptibility to oxidative metabolism by cytochrome P450 enzymes, potentially improving the in vitro half-life of peptide leads.
• Conformational constraint: Steric bulk near the α-carbon and on the aromatic ring can restrict the backbone dihedral angles (φ, ψ) and side-chain rotamer distribution, helping to pre-organize a peptide into its bioactive conformation.
• SAR exploration: Systematic replacement of phenylalanine with ring-substituted analogs (2-methyl, 4-methyl, 2,4-dimethyl) allows medicinal chemists to map receptor binding pockets and optimize potency and selectivity.
• Peptidomimetics: Incorporation into cyclic peptides, stapled peptides, or peptide–drug conjugates where a defined hydrophobic pharmacophore is required.

These properties make Fmoc-2,4-Dimethyl-L-phenylalanine a valuable tool for researchers working on G protein-coupled receptor (GPCR) ligands, protease inhibitors, antimicrobial peptides, and cell-penetrating peptides.

Handling, Storage, and Quality Considerations

As with all Fmoc-protected amino acid building blocks, proper handling of Fmoc-2,4-Dimethyl-L-phenylalanine is important to maintain reagent integrity:

• Storage: Store in a cool, dry environment away from light and moisture. Refrigerated storage (2–8 °C) in a sealed container under inert atmosphere is generally recommended for long-term stability of Fmoc amino acids.
• Moisture sensitivity: Fmoc amino acids are susceptible to hydrolysis of the activated ester intermediate if reagents are not adequately dried. Always equilibrate to room temperature before opening containers to prevent condensation.
• Solubility: This building block is typically soluble in polar aprotic solvents commonly used in SPPS, such as DMF and NMP. Sonication or mild warming may assist dissolution at higher concentrations.
• Purity: For reliable synthesis outcomes, use reagents of verified high purity (≥98% by HPLC is typical for research-grade Fmoc amino acids). Review the certificate of analysis (CoA) supplied with each lot.

Users should consult the safety data sheet (SDS) prior to use and follow standard laboratory safety precautions for handling fine chemical powders.

Frequently asked questions

What makes Fmoc-2,4-Dimethyl-L-phenylalanine different from standard Fmoc-L-phenylalanine?

Fmoc-2,4-Dimethyl-L-phenylalanine carries methyl groups at the 2- (ortho) and 4- (para) positions of the phenyl ring, increasing steric bulk, altering aromatic electronics, and potentially improving the metabolic stability and conformational rigidity of peptides incorporating it compared to the unsubstituted parent amino acid.

Are special coupling conditions required for this building block in Fmoc SPPS?

The ortho-methyl group introduces steric hindrance near the carbonyl, which can reduce coupling efficiency. Double-coupling cycles and the use of highly reactive activating reagents such as HATU combined with a hindered base (e.g., 2,6-lutidine) are recommended, especially when flanking residues are also sterically demanding. Completion of each coupling step should be monitored by a Kaiser or chloranil test.

Does Fmoc-2,4-Dimethyl-L-phenylalanine require side-chain protection during Fmoc SPPS?

No additional side-chain protection is required. The 2,4-dimethylphenyl side chain is chemically inert under standard Fmoc SPPS conditions, including piperidine-mediated Fmoc removal and TFA-mediated global deprotection and cleavage. Only the α-amine Fmoc group needs to be removed during each synthesis cycle.

What solvents are suitable for dissolving Fmoc-2,4-Dimethyl-L-phenylalanine?

Fmoc-protected amino acids, including this derivative, are generally soluble in polar aprotic solvents such as DMF and NMP, which are the standard solvents used in Fmoc SPPS. If solubility is limited at the desired concentration, gentle sonication or mild warming can be applied. Avoid protic solvents such as water for working solutions, as these can promote hydrolysis of activated intermediates.

In what types of peptide research is this building block most commonly used?

Fmoc-2,4-Dimethyl-L-phenylalanine is particularly useful in medicinal chemistry SAR studies, peptidomimetic design, and the development of metabolically stable peptide drug candidates. It is applied in research on GPCR ligands, enzyme inhibitors, antimicrobial peptides, and any project requiring fine-tuning of aromatic side-chain geometry and hydrophobicity.

References

1. Chan, W.C.; White, P.D. (Eds.) Fmoc Solid Phase Peptide Synthesis: A Practical Approach. Oxford University Press, 2000.
2. Coin, I.; Beyermann, M.; Bienert, M. Solid-phase peptide synthesis: from standard procedures to the synthesis of difficult sequences. Nature Protocols, 2007, 2, 3247–3256. doi:10.1038/nprot.2007.454
3. Doedens, L.; Opperer, F.; Cai, M.; Beck, J.G.; Dedek, M.; Palmer, E.; Hruby, V.J.; Kessler, H. Multiple N-methylation of MT-II backbone amide bonds leads to melanocortin receptor subtype hMC1R selectivity: pharmacological and conformational studies. Journal of the American Chemical Society, 2010, 132, 8115–8128. doi:10.1021/ja101428m

Products are supplied for research and development use only. Not for use in humans, animals, diagnosis, or therapy.